6th April 2011
Cello is pleased to announce the appointment of Stephen Highley as Group Corporate Development Director, reporting to the Board of Cello.
Stephen Highley was one of the three founders of MSI, which was acquired by Cello in 2007 and which is now the Group’s primary pharmaceutical consulting business. He has spent the majority of his career in the pharmaceutical sector, working on a wide range of strategic and marketing related issues for major pharmaceutical clients. He has worked closely with the Board of Cello on the preparation and execution of the Group’s healthcare strategy, most recently including the acquisition of MedErgy HealthGroup Inc. in March 2011.
Mark Scott, Chief Executive of Cello, commented
“I wish to congratulate Stephen on his new role. Cello is committed to strengthening its position as a leading global service supplier to the pharmaceutical and broader healthcare sector and Stephen will bring both his detailed sector knowledge and huge energy to fulfilling this strategy.”